Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 2 | -$0.10 | -$0.08 | -$0.09 |
Q2 2025 | 1 | -$0.04 | -$0.04 | -$0.04 |
Q3 2025 | 1 | -$0.00 | -$0.00 | -$0.00 |
Q4 2025 | 1 | -$0.09 | -$0.07 | -$0.08 |
Q1 2026 | 1 | -$0.09 | -$0.07 | -$0.08 |
Q2 2026 | 1 | -$0.09 | -$0.07 | -$0.08 |
Q3 2026 | 1 | -$0.09 | -$0.07 | -$0.08 |
Surmodics, Inc. last posted its earnings results on Thursday, January 30th, 2025. The company reported $-0.04 earnings per share for the quarter, topping analysts' consensus estimates of $-0.12 by $0.08. The company had revenue of 29.92 M for the quarter and had revenue of 126.08 M for the year. Surmodics, Inc. has generated $-1 earnings per share over the last year ($-0.82 diluted earnings per share) and currently has a price-to-earnings ratio of -26.38. Surmodics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 30th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
01/30/2025 | Q1 2025 | -$0.12 | -$0.26 | -0.14 | $33.37 M | $29.92 M |
11/20/2024 | Q4 2024 | N/A | -$0.24 | N/A | $30.40 M | $33.23 M |
07/31/2024 | Q3 2024 | -$0.31 | -$0.53 | -0.22 | $29.95 M | $30.34 M |
05/01/2024 | Q2 2024 | -$0.36 | $0.02 | 0.38 | N/A | $31.96 M |
02/01/2024 | Q1 2024 | -$0.30 | -$0.06 | 0.24 | $29.64 M | $30.55 M |
11/22/2023 | Q4 2023 | N/A | $0.48 | N/A | $26.27 M | $27.97 M |
08/02/2023 | Q3 2023 | $0.05 | $0.52 | 0.47 | $26.18 M | $52.48 M |
04/26/2023 | Q2 2023 | -$0.49 | -$0.55 | -0.06 | N/A | $27.20 M |
02/06/2023 | Q1 2023 | -$0.64 | -$0.56 | 0.08 | N/A | $24.93 M |
11/23/2022 | Q4 2022 | N/A | -$1.06 | N/A | $24.09 M | $25.99 M |
07/27/2022 | Q3 2022 | -$0.39 | -$0.41 | -0.02 | $25.19 M | $24.85 M |
04/27/2022 | Q2 2022 | -$0.32 | -$0.29 | 0.03 | N/A | $26.11 M |
02/03/2022 | Q1 2022 | N/A | -$0.20 | N/A | N/A | $23.00 M |
11/24/2021 | Q4 2021 | N/A | -$0.02 | N/A | $23.06 M | $23.97 M |
08/04/2021 | Q3 2021 | -$0.11 | -$0.24 | -0.13 | $23.31 M | $23.87 M |
04/28/2021 | Q2 2021 | $0.63 | $0.59 | -0.04 | N/A | $35.00 M |
02/09/2021 | Q1 2021 | -$0.06 | -$0.02 | 0.04 | N/A | $22.30 M |
12/02/2020 | Q4 2020 | N/A | -$0.22 | N/A | $20.77 M | $22.54 M |
08/05/2020 | Q3 2020 | $0.19 | $0.18 | -0.01 | $23.75 M | $26.88 M |
04/29/2020 | Q2 2020 | N/A | $0.11 | N/A | N/A | $22.82 M |
Surmodics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 30th, 2025 based offlast year's report dates.
In the previous quarter, Surmodics, Inc. (:SRDX) reported $-0.04 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.12 by $0.08.
The conference call for Surmodics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Surmodics, Inc.'s latest earnings report can be read online.
Surmodics, Inc. (:SRDX) has a recorded annual revenue of $126.08 M.
Surmodics, Inc. (:SRDX) has a recorded net income of $-11,542,000.Surmodics, Inc. has generated $-0.82 earnings per share over the last four quarters.
Surmodics, Inc. (:SRDX) has a price-to-earnings ratio of -26.38 and price/earnings-to-growth ratio is 1.07.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED